<DOC>
	<DOCNO>NCT02456363</DOCNO>
	<brief_summary>Assessed use ( 1 ) Adalimumab ( Humira ) NSAIDs ( 2 ) Use Adalimumab ( Humira ) treatment ankylose spondylitis patient safety efficacy .</brief_summary>
	<brief_title>Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis</brief_title>
	<detailed_description>In study , single center , treatment , open , randomize , control clinical trial ass Adalimumab ( Humira ) style NSAIDs treatment patient ankylose spondylitis , total 300 expect included consent form sign subject , randomly assign treatment group control group 150 people . Subjects return first week outpatient follow 0,8,20,44,68,92 accept routine physical examination ( weight , blood pressure , etc . ) , AS Scale ( BASDAI , BASFI , BAS-G ) , fingertip ground test , lumbar range motion , chest expansion test , lateral bend test , occipital bone measurement , physician global assessment ( Physician global assessment ) , patient pain score ( VAS ) , AS quality Life scale ( ASQOL ) , SF-36 quality life scale , Complete joint assessment , ASAS20 response criterion , assessment laboratory analysis inflammation index ( HS-CRP , IgA , ESR ) , safety index check ( CBC , SGPT , Serum creatinine , HBV-DNA HbsAg ( + ) , HCV -RNA HCVAB . Subjects need return OPD week 0 , accept Anti-HBs , Anti-HBc , HBsAg , Anti-HCV . Subjects require return first outpatient follow 0,20,92 week , pulmonary function test . Therefore , subject 92 week trial , total need blood six time , time blood 10 cc . And assess side effect adverse event ( Adverse Event , AE ) , serious adverse event ( Serious Adverse Event , SAE )</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<criteria>Age â‰¥18 year old HLA B27 positive X ray examination Clinical symptom physical examination , follow three condition subject least two : i.lower back pain morning stiffness symptom persist 3 month ii . lumbar activity restrict iii . chest expansion restrict Active disease four week ( continue two examination BASDAI &gt; 6 , ESR &gt; 28 mm/1 hr CRP &gt; 1 mg/dl ) pregnant breastfeed woman patient active infection highly infectious patient Cancer precancerous condition patient multiple sclerosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Adalimumab</keyword>
	<keyword>NSAIDs</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
</DOC>